TG Therap (TGTX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov5

Company Announces Q3 2025 Earnings Beat, Plans Continued Commercialization of BRIUMVI

22:12

Nov3

TG Therapeutics Reports Exceeding Expectations in Briumvi Revenue and Upgrading 2025 Revenue Guidance

19:06

TG Therap released FY2025 Q3 earnings on November 3 Pre-Market (EST), actual revenue USD 161.71 M (forecast USD 152.17 M), actual EPS USD 2.4299 (forecast USD 0.2201)

14:30

TG Therap released FY2025 9 Months Earnings on November 3 Pre-Market EST, Actual Revenue: USD 423.71 M, Actual EPS: USD 2.6299

14:30

Oct28

TG Therapeutics Completes Phase 3 ENHANCE Trial Enrollment for BRIUMVI® New Regimen for Relapsing MS

11:30

Oct27

TG Therap to Release FY2025 Q3 Earnings on November 3, Pre-Market EST; Forecast Revenue USD 152.17 M, EPS USD 0.2156

00:05

Schedules & Filings

Schedules

Filings

Nov3

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 161.71 M, Net Income 390.9 M, EPS 2.4299

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 141.15 M, Net Income 28.19 M, EPS 0.17

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 120.86 M, Net Income 5.06 M, EPS 0.0299

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change